医学部

uchida hiroki

  (内田 大樹)

Profile Information

Affiliation
School of Medicine, Faculty of Medicine, Fujita Health University
Degree
博士(医学)

J-GLOBAL ID
201501012421863878
researchmap Member ID
7000012915

Misc.

 9
  • Hiroki Uchida, Tsuneo Imai, Toyone Kikumori, Hironori Hayashi, Shigenori Sato, Sumiyo Noda, Ai Idota, Tetsuya Kiuchi
    Surgery Today, 43(8) 848-853, Aug, 2013  Peer-reviewed
    Purpose: Surgical treatment of local recurrent papillary thyroid carcinoma is still controversial because of the increased morbidity in comparison to primary surgery, and the unclear efficacy. This study analyzed the efficacy and safety of surgery for recurrent disease. Methods: A retrospective cohort analysis of 86 patients who underwent surgery for local recurrent papillary thyroid carcinoma at a single institution during the period 1979-2009. Results: The cause-specific survival rates of all patients at 5, 10, and 20 years were 86 % (95 % CI 77-95 %), 74 % (95 % CI 62-87 %), and 36 % (95 % CI 18-54 %), respectively. A univariate analysis found that gender, age &gt 45 years at reoperation and macroscopic non-curative surgery for recurrence affected the cause-specific survival rates. The latter two features remained significant in a multivariate analysis. Permanent recurrent nerve paralysis and hypoparathyroidism developed in 4 (4.7 %) and 5 (5.8 %) patients, respectively. Conclusions: Surgery for local recurrent papillary thyroid carcinoma could be effective when macroscopic curative dissection was possible, and that the procedure was safe and was associated with minimal morbidity. Therefore, repeat surgery for local recurrent papillary thyroid carcinoma is worthwhile. © 2012 Springer Japan.
  • 野村尚弘, 山下克也, 内田大樹, 武藤俊博, 岡本喜一郎, 佐藤健, 市原透
    胆と膵, 34(6) 503-508, 2013  Peer-reviewed
  • 野村尚弘, 山下克也, 内田大樹, 武藤俊博, 岡本喜一郎, 佐藤健, 市原透
    癌と化学療法, 40(9) 1225-1228, 2013  Peer-reviewed
  • Masataka Sawaki, Shigenori Sato, Sumiyo Noda, Ai Idota, Hiroki Uchida, Nobuyuki Tsunoda, Toyone Kikumori, Yuichi Aoyama, Shunichi Ishihara, Yoshiyuki Itoh, Tsuneo Imai
    BREAST CANCER, 19(4) 353-359, Oct, 2012  Peer-reviewed
    Intraoperative radiotherapy (IORT) is under evaluation in breast-conserving surgery. We have begun our study with the first step being a phase I-II study. This study was designed to identify the recommended dose and to test the feasibility of and tolerance to IORT in Japanese patients (UMIN000000918). A phase I study was designed using a scheme of dose escalation from 19 to 20 to 21 Gy. We designed the phase II study to use the recommended dose. The primary endpoint was early toxicity. Secondary endpoints were efficacy for a long period and late toxicity. Inclusion criteria included the following: (1) T < 2.5 cm, (2) age > 50 years, (3) surgical margin > 1 cm, (4) intraoperative pathologically free margins, and (5) sentinel node negative. Partial resection was performed with at least a 1 cm margin around the tumor. Radiation was delivered directly to the mammary gland with the use of a Mobetron(A (R)). The toxicity was evaluated with the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Nine patients were enrolled for the phase I study. All patients tolerated and we therefore recommend 21 Gy. The following 23 patients were enrolled in a phase II study and received 21 Gy. After a median follow-up of 26.0 months, their toxicities within 3 months included deep connective tissue fibrosis (G1 23/26, G2 2/26), hematoma (G1 9/26), infection in the musculoskeletal soft tissue (G1 4/26), and soft tissue necrosis (G2 3/26). There have been no local recurrences. The first group of Japanese female patients treated with IORT showed very good tolerability in the phase I/II study.
  • 野田 純代, 伊藤 和子, 井戸田 愛, 内田 大樹, 佐藤 成憲, 林 裕倫, 菊森 豊根, 今井 常夫
    日本内分泌・甲状腺外科学会雑誌, 29(1) 62-65, 2012  Peer-reviewed

Presentations

 52